Tech Observer’s Post

I am excited to join our friends in Singapore and speak at the DEFINITE Care Journal Club about building trustworthy Generative AI for healthcare. If you are not aware of it, Singapore has a vibrant environment; Suzy Engwall posted an article on how it has surpassed Beijing in innovation and startup environment. #health #innovation #generativeai

Why conduct your study in Taiwan? Shanny Chen explains why. Learn more from the George Clinical team at BIO Asia–Taiwan. Reach out to Jake L. to set up a time to talk. #ScienceServiceSolutions #ImprovingHealthWorldwide #NooneLeftBehind #ClinicalTrials #Taiwan

Register for the 9th International Casemix Conference 2024 Casemix as Tool for Strategic Purchasing in Health Financing 🗓 30th September to 2nd October 2024 🇲🇾 The Everly Hotel, Putrajaya, Malaysia The 9th International Casemix Conference 2024 will bring together experts worldwide to discuss how Casemix Systems can be a strategic tool for health financing, particularly in developing countries. What is Casemix? Casemix is a system that groups patients into categories based on their diagnoses and resource use. Using Casemix and Diagnosis Related Groups (DRGs) allows for a fairer allocation of resources and helps ensure cost-consciousness and cost-effectiveness in healthcare delivery. Why attend the conference? 🤝 Share and learn best practices with colleagues worldwide to discuss their experiences with Casemix as a tool for strategic purchasing in health financing, particularly from developing countries. 👥 Network with key stakeholders, policymakers, practitioners, and others in the field. ✍🏼 Registration is now open! https://lnkd.in/gYUZ6XnE Don't miss this opportunity to learn, share, and network with leading experts in Casemix Systems. Organisers and Collaborating Partners: Malaysian Health Economics Association (MAHEA) Casemix Solutions Sdn. Bhd. Ministry of Health Malaysia Pusat Antarabangsa Casemix & Pengekodan Klinikal, Universiti Kebangsaan Malaysia (ITCC-UKM) Universitas Andalas (UNAND) Universiti Sains Malaysia (USM) Universiti Malaya Medical Centre (UMMC) Universiti Sains Islam Malaysia (USIM) Aznida Firzah Abdul Aziz #Casemix #HealthcareFinancing #StrategicPurchasing #HealthEconomics #Malaysia

South Korea has emerged as one of the major centers of innovation in the global healthcare industry, thanks to technological advancements, medical research, and supportive health policies. Over the past few decades, the country has undergone a significant transformation in the healthcare sector, making it one of the leaders in Asia and around the world. Overall, the development of the healthcare industry in South Korea reflects the country's commitment to innovation and improving quality of life. With technological advancements, growing research, and supportive policies, South Korea has the potential to continue to be a pioneer in the global health sector. Jababeka is very ready to be open to Korean Investors to invest in Jababeka with Biotech Industrial Cluster and Medical City Masterplan. Further information: Mobile/Wa: 0812-8309-0900 www.jababeka.com Follow our Social Media: Instagram : @jababekaindustrialestate Facebook Page : @jababekaindustrialestate #Korean #KoreanInvestor #Healthcare #jababeka #jababekaindustrialcluster #jababekaindustrialestate #jedihub #jababekaecommercedigitalhub #jababekaecommerceindustrialpark #ecommerceindustrialpark #ecommercehub #digitalhub #startupcluster #jababekabiotechcluster #biotechcluster #biomedicalpark #biotechnology #jababekahalalcluster #halalcluster #smartmanufacturinghub #indonesia #singapore #malaysia #japan #southkorea #propertyinvestment #realestate

Unlike in developed countries where RWD is well commercialized (well, sort of), RWD business in emerging markets is hard to grow. One solution is to create a special zone for RWD, with specialized policies to stimulate its growth. Hainan is such a magical island of RWD/E in China; Telangana may be an RWE heaven in India. But can this model, created by government, survive and flourish in free market? In 2024 Chinese Medical Affairs Conference, a group of RWD/E scientists discussed this question. From left, Prof Yang Yu, West China Hospital; Dr. Li Xie, Head of RWE, Happy Life Tech; Dr. Sha Tao, Head of RWE China, Roche; myself; Dr. Yue Wang, Head of Digital Med, AZ China; Lisa Sun, General Manager, TigerMed; Dr. Tony Guo, VP IQVIA. What did we learn during the 2 hour discussion? With strong support from government, it’s easy to survive. But to flourish, they need to go out of the comfort zone and open its mind for collaboration.

Our HVL x Taiwan webinar is uploaded here!! Special thanks to Cortilia L., National Taiwan University and TMU BioMed Accelerator for help with co-hosting and organizing Would like to acknowledge our speakers Cortilia L. of Kyalio - Prefers multi-market entry strategy. Taiwan and Singapore primary to specialist referral process different as well as the investor appetite - SG has more risk appetite for proof of concept but the business case must be sound Dr. Nolnabhas Yaemsaard of patRangsit Hospital Group and Alyssa Global Thailand's robust medical tourism, wide UHC coverage and the rise of NCD and aging population makes it a good opportunity for specialty service providers Lucas Fortier of POC Pharma Different purchase drivers at patient to pharmacist to Rx level can be analyzed at the country as well as brand/category of the drugs And our special guest, former Secretary of Health of the Philippines, Dr Manuel Dayrit In the Philippines, tertiary care is more developed than the primary facilities, and private sector comprises 60-70% of all healthcare expenditure. Public sector is more complex compared to private, need to deal with Philhealth. Implications for JV is 1) engagement with govt thru outsourcing or JV, 2) engagement with private sector through partnerships to market and use in the country. New tech, easier to bring as a part of a larger existing solution than a standalone. Recording of the event is here: https://lnkd.in/gwEBWfNy #ASEAN, #publicprivate, #marketentry

#Mirxes is honoured and delighted to be the only life sciences company hosting Mr Paul Chan, Hong Kong's Financial Secretary, during his visit to Hangzhou and Suzhou last week. Our Co-Founders, Dr Lihan Zhou (CEO) and Dr Zou Ruiyang (CTO), shared our growth journey from Singapore start-up to becoming a leader in precision medicine through #innovation, #commercialisation, #internationalisation, and strong public-private partnerships. We also showcased our maturing clinical pipeline, advanced facilities, and plans to expand market share in Northeast Asia with our early cancer detection products, anchored by our existing presence in Hangzhou and Hong Kong. We were impressed by Mr Chan's insights into Hong Kong's economic transformation, particularly the focus on Life and Health Technology as one of their four strategic industries. This aligns perfectly with Mirxes' mission to accelerate access to novel and life-saving cancer diagnostics for the vast 2.4 billion population across Northeast and Southeast Asia. Mr Chan also shared about the Office for Attracting Strategic Enterprises (OASES) and the HK$30 billion “Co-Investment Fund” under Hong Kong Investment Corporation to attract strategic enterprises to invest and operate in Hong Kong. We believe strongly in Singapore and Hong Kong’s critical and synergistic roles in driving life sciences innovation, commercialisation, and capital market access, for the benefit of the region and the populations under-served by precision medicine.  Mirxes is committed to saving lives and reducing healthcare burden through early detection, leveraging the strength of the Singapore and Hong Kong ecosystems. #preventivehealthcare #precisionmedicine #biotech #cancerearlydetection #earlydetection #earlydetectionsaveslives #innovation #globalpartnership #publicprivatepartnership

Tomorrow we will introduce ongoing melanoma research in Turku!

And so it begins…in such a short time after the official MyGenom project was launched in Malaysia, the team at NIBM Malaysia are already recruiting participants. 🙌 This first of its kind in Malaysia, this large-scale population genome study will establish a reference genome based on 2400 healthy individuals to be expanded in the next phase to reach 10,000. Malaysia has been an important piece of puzzle to the global map of peopling and migration history, owing to its strategic location at the crossroad of the mainland and islands of SEA. It is a multi-ethnic, multi-lingual, and multi-cultural nation with diverse socio-economic practices. (Hoh, Deng and Xu, 2022) https://lnkd.in/g5YXwQvp I strongly believe that understanding diversity in genomic data is paramount to solving some of the world’s toughest health challenges. To ensure that genomes can be interpreted in the appropriate context of global diversity, we aim to increase the equity of representation in genomic data. With equitable representation, therapies and solutions can be attuned to a broader set of genomes, therefore decreasing an inherent bias for the medicines of the future. And Illumina is pleased to be chosen as the sequencing technology partner for the MyGenom project. 🧬 🤝 Through our latest sequencing technology and software tools we look forward to accelerating the MyGenom project and supporting the ministries’ goal to sequence more genomes and identify genes involved in both rare and common diseases whilst enabling sharing of genomic data for analysis, research and clinical applications. Nicholas Tan Martin Hutagalung Helen Speirs Graeme Bethel Gregory Essert

We are thrilled to announce that the MyGenom study, a collaborative research effort between the Ministry of Science, Technology and Innovation (MOSTI) and the Ministry of Health (MOH) Malaysia, is now seeking healthy Malaysian participants. Our goal is to develop a reference genome that reflects the rich and diverse Malaysian population. This will pave the way for the advancement of precision medicine in Malaysia. We are currently inviting Malaysian adults over 18 years old, from all ethnic backgrounds and genders 👩🏻🧑🏻, who are in good health 💪🏻to join this nationwide study. What’s Involved: •⁠ ⁠Blood Sample: ~25 mL🩸 •⁠ ⁠Body composition 📝  •⁠ Heart rhythm screening 💌 •⁠ ⁠Questionnaire: Answering a set of questions on lifestyle, dietary patterns and family medical history 📋 •⁠ ⁠Cognitive Assessment 🧠 What You’ll Get: •⁠ ⁠Free health screening results 🩺 •⁠ Free heart screening 💌 •⁠ ⁠Remuneration 🎁 Interested? Fill out the link provided to book an appointment at the nearest recruitment center and be a part of this transformative project! Help us shape the future of healthcare in Malaysia by contributing to this important research. We are excited to have you on board! 🔗 [https://shorturl.at/jwncS] #MyGENOM #PrecisionMedicine #Research #Health #Malaysia #NIH #MGVI